PHARMACY

Merck set to launch Tredaptive in international markets

BY Alaric DeArment

WHITEHOUSE STATION, N.J. Merck & Co. plans to launch a new lipid-modifying drug in international markets later this year, though it remains under investigation in the United States.

The company announced that it would launch Tredaptive (extended-release niacin and laropiprant) by third quarter in Mexico, the United Kingdom, Germany and 36 other countries. The drug also goes by the brand name Cordaptive.

“Merck is pleased that we are now able to supply Tredaptive in approved markets and continue our long-standing commitment to help address unmet medical needs in cardiovascular care,” Merck Research Laboratories franchise head and SVP atherosclerosis and cardiovascular Luciano Rossetti stated.

The drug is designed to treat mixed dyslipidemia and primary hypercholesterolemia.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Bartell Drugs sponsors ‘Stock the Pantry’ food drive

BY Alaric DeArment

SEATTLE Bartell Drugs has announced its sponsorship of its “Stock the Pantry” food drive to benefit a local food bank.

The regional chain said it would accept donations of nonperishable food for the organization Northwest Harvest at its 55 stores in the Seattle area from June 1 to 14.

The drive is designed to benefit families that depend on free or reduced-price school lunches during the summer months, when they may struggle to provide those meals at home.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA tenatively approves Teva pink eye generic

BY Alaric DeArment

ROCKVILLE, Md. The Food and Drug Administration has given tentative approval to Teva Pharmaceutical Industries for its generic version of a drug for eye infections, FDA records showed.

The agency gave Teva the tentative approval for its moxifloxacin hydrochloride ophthalmic solution in the 0.5% strength. The solution is a generic version of Alcon’s Vigamox, which is used to treat bacterial conjunctivitis, commonly known as pink eye.

Alcon does not list the sales figures for Vigamox, though it reported sales of drugs to treat infections and inflammations of $882.5 million for 2008 in Securities and Exchange Commission filings.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?